MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points MaxCyte Inc ( NASDAQ:MXCT ) reported $6.8 million in total revenue for Q3 2025, aligning with expectations despite a challenging operating environment. The company signed a new strategic platform license with Moonlight Bio, bringing the total number of signed SPLs to four this year, consistent with their guidance. MaxCyte Inc ( NASDAQ:MXCT ) anticipates five of its current 18 clinical programs to enter pivotal studies in the next 6 to 18 months, with potential commercial launches in 2027 and 2028. The company expects to realize $17 to $19 million in annualized savings from a restructuring initiative, which includes a 34% workforce reduction. MaxCyte Inc ( NASDAQ:MXCT ) maintains a strong cash position with $158 million in cash equivalents and investments, providing a solid financial foundation for future growth. Negative Points Total revenue for Q3 2025
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO [Yahoo! Finance]Yahoo! Finance
- Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPOBusiness Wire
- MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- MaxCyte (NASDAQ:MXCT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MXCT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- MaxCyte (NASDAQ:MXCT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MXCT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
MXCT
Earnings
- 11/12/25 - Miss
MXCT
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- 11/5/25 - Form 8-K
- MXCT's page on the SEC website